change the order of the amendments established by House Resolution 350.

Mr. WYNN. I thank the Chair.

AMENDMENT NO. 4 OFFERED BY MRS. BOYDA OF KANSAS

The Acting CHAIRMAN. It is now in order to consider amendment No. 4 printed in House Report 110–118.

Mrs. BOYDA of Kansas. Madam Chairman, I offer an amendment.

The Acting CHAIRMAN. The Clerk will designate the amendment.

The text of the amendment is as follows:

Amendment No. 4 offered by Mrs. BOYDA of Kansas:

In section 204, in the proposed section 28(c)(2), insert '', to include the replacement of petroleum-based materials,'' after ''benefits to the Nation''.

The Acting CHAIRMAN. Pursuant to House Resolution 350, the gentlewoman from Kansas (Mrs. BOYDA) and a Member opposed each will control 5 minutes.

The Chair recognizes the gentlewoman from Kansas.

Mrs. BOYDA of Kansas. Madam Chairman, I appreciate the Chairman's willingness to highlight the potential cost savings to the Nation through the research and commercialization of plastics technology utilizing renewable energy sources for common plastics applications. I hope that the Director of the National Institute of Technology will give attention to the collaborative efforts between universities and small and medium-sized businesses in the development of economical methods of manufacturing common plastic items from renewable energy sources.

I yield to the gentleman from Oregon.

Mr. WU. Madam Chairman, I want to assure the gentlelady from Kansas that we will be happy to work with her to address her concerns as this bill moves through the legislative process.

Mrs. BOYDA of Kansas. I ask unanimous consent to withdraw the amendment.

The Acting CHAIRMAN. Without objection, the amendment is withdrawn.

There was no objection.

The Acting CHAIRMAN. It is now in order to consider amendment No. 5 printed in House Report 110–118.

Mr. WU. Madam Chairman, I move that the Committee do now rise.

The motion was agreed to.

Accordingly, the Committee rose; and the Speaker pro tempore (Mr. SCOTT of Virginia) having assumed the chair, Mrs. TAUSCHER, Acting Chairman of the Committee of the Whole House on the state of the Union, reported that that Committee, having had under consideration the bill (H.R. 1868) to authorize appropriations for the National Institute of Standards and Technology for fiscal years 2008, 2009, and 2010, and for other purposes, had come to no resolution thereon.

PERMISSION TO CONSIDER AMENDMENT OUT OF ORDER DURING FURTHER CONSIDERATION OF H.R. 1868, TECHNOLOGY INNOVATION AND MANUFACTURING STIMULATION ACT OF 2007

Mr. WYNN. Mr. Speaker, I ask unanimous consent that during further consideration of H.R. 1868 in the Committee of the Whole, pursuant to H. Res. 350, that amendment No. 2 may be offered out of order.

The SPEAKER pro tempore. Is there objection to the request of the gentleman from Maryland?

There was no objection.

TECHNOLOGY INNOVATION AND MANUFACTURING STIMULATION ACT OF 2007

The SPEAKER pro tempore. Pursuant to House Resolution 350 and rule XVIII, the Chair declares the House in the Committee of the Whole House on the state of the Union for the further consideration of the bill, H.R. 1868.

□ 1426

IN THE COMMITTEE OF THE WHOLE

Accordingly, the House resolved itself into the Committee of the Whole House on the state of the Union for the further consideration of the bill (H.R. 1868) to authorize appropriations for the National Institute of Standards and Technology for fiscal years 2008, 2009, and 2010, and for other purposes, with Mrs. TAUSCHER (Acting Chairman) in the chair.

The Clerk read the title of the bill.

The Acting CHAIRMAN. When the Committee of the Whole rose earlier today, amendment No. 3 offered by the gentleman from Illinois (Mr. MANZULLO) had been disposed of.

AMENDMENT NO. 2 OFFERED BY MR. WYNN

The Acting CHAIRMAN. It is now in order to consider amendment No. 2 printed in House Report 110–118.

Mr. WYNN. Madam Chairman, I offer an amendment.

The Acting CHAIRMAN. The Clerk will designate the amendment.

The text of the amendment is as follows:

Amendment No. 2 offered by Mr. WYNN:

In section 204, in the proposed section 28(b)(1), insert ''(including any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use)'' after ''enabling technologies''.

The Acting CHAIRMAN. Pursuant to House Resolution 350, the gentleman from Maryland (Mr. WYNN) and a Member opposed each will control 5 minutes.

The Chair recognizes the gentleman from Maryland.

Mr. WYNN. Madam Chair, the amendment that I am proposing will make sure that the biotechnology research and innovation are included under TIP's funding objectives by expanding the definition of enabling technologies in section 204 of the bill to include ''any technological application that uses biological systems, living organisms or derivatives thereof to make or modify products or processes for specific use.''

Biotechnology is an emerging segment of the technology sector often overlooked as an excellent source of manufacturing jobs and research and development. The biotechnology industry is a driving force in the Maryland economy and a rising sector of the American economy.

In the United States, the biotechnology industry has created more than 200 new therapies and vaccines, including products to treat cancer, diabetes, HIV/AIDS and anti-autoimmune disorders.

The industry continues to develop innovative therapies over 400 products are currently in clinical trials targeting over 200 diseases. The biotechnology industry is comprised of mostly small start-ups that don't have an existing stream of revenue and are years away from product commercialization. It takes at least 8 years, and then up to $1.2 billion to get a biotechnology therapy approved.

It is these small companies, many of which will never see a product come to market or turn a product that are undertaking the bulk of early development gambles and working toward innovative cures. In fact, small biotech companies account for two-thirds of the industry's pipeline.

In 2005, there were 1,400 biotech companies in the United States, but only 329 were publicly traded. The majority of the Biotechnology Industry Organization's (BIO) members are small companies that have fewer than 50 employees.

The U.S. is the leader in biotechnology. The number of products in the late stage pipeline in the U.S. has double the number of products in the E.U. This is largely due to the fact that per capita biotech R&D in the U.S. is 574 percent higher than in the E.U.

□ 1430

My State of Maryland is a leader among States in biotechnology research and innovation, and Maryland-based businesses will benefit greatly from the funding awarded under this bill. But not only Maryland; other small startup companies in the biotech industry will benefit by inclusion of this bill.

I believe it is a simple, straightforward amendment that just expands and clarifies the fact that biotechnology companies should be included, and I ask support for the amendment.

Mr. WU. Madam Chairman, will the gentleman yield?

Mr. WYNN. I would be happy to yield.

Mr. WU. Madam Chairman, on the Science and Technology Committee we are keenly aware of the importance of the biotechnology industry to our economy. We also know that the